Interferon alpha induces a stronger antiviral effect than interferon lambda in HBV/HDV infected humanized mice.

HBV DNA HBsAg HDV RNA human albumin humanized mice, interferon alpha interferon lambda

Journal

Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979

Informations de publication

Date de publication:
19 Aug 2024
Historique:
received: 21 05 2024
revised: 22 07 2024
accepted: 14 08 2024
medline: 22 8 2024
pubmed: 22 8 2024
entrez: 21 8 2024
Statut: aheadofprint

Résumé

Recent studies indicate that treatment of chronic hepatitis D virus (HDV) with either pegylated interferon (IFN)λ or pegylated IFNα monotherapy leads to a dramatic decline in HDV RNA. Herein, we investigated the innate antiviral efficacy of IFNλ and IFNα in humanized mice that lack an adaptive immune response. Humanized mice were either co-infected with hepatitis B virus (HBV) and HDV simultaneously, or HDV infection was performed subsequent to HBV infection (i.e., superinfected). After steady viral replication was achieved, mice received either IFNλ (n=6) or IFNα (n=7) for 12 (or 13) weeks. Pretreatment median levels of serum HBV DNA (8.8 [IQR:0.2] log IU/ml), HDV RNA (9.8 [0.5] log IU/ml), HBsAg (4.0 [0.4] log IU/ml) and human albumin, hAlb (6.9 [0.1] log ng/mL) were similar between mice treated with IFNα or IFNλ and between those coinfected versus superinfected. Compared to mice treated with IFNλ, mice treated with IFNα had a significantly greater decline in HBV, HDV, and HBsAg levels. In conclusion, IFNα induces stronger inhibition of HBV and HDV than IFNλ in humanized mice that lack an adaptive immune response. Further studies are needed to assess the respective role of the combined innate-and adaptive-immune systems in the treatment of HBV and HDV with IFNα and IFNλ.

Identifiants

pubmed: 39168375
pii: S0168-1702(24)00144-8
doi: 10.1016/j.virusres.2024.199451
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199451

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest Kazuaki Chayama has received honoraria from Bristol-Myers Squibb and MSD K.K., AbbVie, Gilead Science, Dainippon Sumitomo Pharma and Mitsubishi Tanabe Pharma and research funding from Gilead Science, Dainippon Sumitomo Pharma, MSD K.K., AbbVie, Eisai, TORAY, Otsuka Pharma, Chugai Pharma, Takeda Pharma and Roche. Jeffrey Glenn, director, and equity holder of Eiger Biopharmaceuticals. Ohad Etzion has received consulting fees from Eiger Biopharmaceuticals. The other authors declare no conflicts of interest that pertain to this work.

Auteurs

Sarah Duehren (S)

The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.

Takuro Uchida (T)

Department of Gastroenterology, Faculty of Medicine, Oita University, Yufu, Japan; Division of Travel Medicine and Health, Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University, Yufu, Japan; Research Center for Hepatology and Gastroenterology, Hiroshima university, Hiroshima, Japan.

Masataka Tsuge (M)

Research Center for Hepatology and Gastroenterology, Hiroshima university, Hiroshima, Japan; Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan; Liver center, Hiroshima University Hospital, Hiroshima, Japan.

Nobuhiko Hiraga (N)

Research Center for Hepatology and Gastroenterology, Hiroshima university, Hiroshima, Japan.

Susan L Uprichard (SL)

The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.

Ohad Etzion (O)

Department of Gastroenterology and Liver Diseases, Soroka University Medical Center, Beer-Sheva, Israel.

Jeffrey Glenn (J)

Division of Gastroenterology and Hepatology, Departments of Medicine, Microbiology & Immunology, Stanford School of Medicine, Stanford, California, USA.

Christopher Koh (C)

Liver Diseases Branch, NIDDK, NIH, USA.

Theo Heller (T)

Liver Diseases Branch, NIDDK, NIH, USA.

Scott J Cotler (SJ)

The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.

Shiro Oka (S)

Research Center for Hepatology and Gastroenterology, Hiroshima university, Hiroshima, Japan; Department of Gastroenterology, Graduate School of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan.

Kazuaki Chayama (K)

Hiroshima Institute of Life Sciences, Hiroshima, Japan; RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.

Harel Dahari (H)

The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, Maywood, Illinois, USA.

Classifications MeSH